跳至主要内容
临床试验/ACTRN12610000427077
ACTRN12610000427077已完成未知

The impact of standard high flux polysulfone versus novel high flux polysulfone (Helixone) dialysis membranes on inflammatory markers in stable haemodialysis patients: A randomised single blinded controlled clinical trial.

Fresenius Medical Care Southeast Asia0 个研究点目标入组 60 人开始时间: 2010年5月26日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • stable haemodialysis patients aged from 18 to 75 years; using established arterio-venous fistulae or fistulae constructed from synthetic grafts; and who had been established on haemodialysis for at least 3 months.

排除标准

  • an inability to give informed consent; unlikely to remain on dialysis for at least 9 months (either due to impending demise or transplantation); prior demonstrated allergy to polysulfone membranes; dialysis via a central venous access catheter; any evidence of an ongoing inflammatory response including infection, auto-immune disorders, vasculitis, treatment with any immunosuppressive agents or the presence of any malignancy.

研究者

发起方
Fresenius Medical Care Southeast Asia

相似试验